KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer (Q36451726)

14 August 2017

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer (English)

1 reference

14 August 2017

1 reference

L A Akslen

1 reference

14 August 2017

J Trovik

1 reference

14 August 2017

C Krakstad

1 reference

14 August 2017

E Birkeland

1 reference

14 August 2017

E Wik

1 reference

14 August 2017

S Mjøs

1 reference

14 August 2017

E A Hoivik

1 reference

14 August 2017

H M J Werner

1 reference

14 August 2017

K Kusonmano

1 reference

14 August 2017

K Petersen

1 reference

14 August 2017

M B Raeder

1 reference

14 August 2017

F Holst

1 reference

14 August 2017

A M Øyan

1 reference

14 August 2017

K-H Kalland

1 reference

14 August 2017

R Simon

1 reference

14 August 2017

H B Salvesen

1 reference

14 August 2017

language of work or name

English

0 references

publication date

25 October 2012

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

107

1 reference

14 August 2017

1 reference

14 August 2017

1997-2004

1 reference

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

RAS oncogenes: weaving a tumorigenic web

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Emerging therapeutic targets in endometrial cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

K-ras codon 12 mutation determines the polypoid growth of colorectral cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Tissue microarrays for high-throughput molecular profiling of tumor specimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516681

The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.477

In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Non–Small Cell Lung Carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.477

Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.477

Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients

21 January 2018

1 reference

12 December 2020

A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients

1 reference

12 December 2020

K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient

1 reference

12 December 2020

Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison

1 reference

12 December 2020

K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome

1 reference

12 December 2020

Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence

1 reference

12 December 2020

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.477

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference

14 August 2017

PubMed publication ID

23099803

1 reference